We are analyzing https://link.springer.com/article/10.1007/s11523-016-0439-4.

Title:
Will Testicular Germ Cell Tumors Remain Untargetable? | Targeted Oncology
Description:
Testicular Germ cell tumors (TGCT) represent the most common solid tumors affecting young men. They constitute a distinct entity because of their embryonic origin and their unique biological behavior. Recently, new preclinical data on genetic and epigenetic susceptibility profiles, biological signaling machinery as well as on molecular patterns of tumors and pathways of pathogenesis helped to elucidate the pathogenesis and the differentiation of TGCTs and to understand the mechanisms behind the development of resistance to treatment. In the present work, we have reviewed new clues to the development, differentiation and progression of TGCTs. We focus on the most important epigenetic and molecular biomarkers, and discussed their diagnostic and prognostic accuracy compared to the currently used biomarkers. The mechanisms underlying the development of resistance to cisplatin and commonly used chemotherapeutic agents are also discussed in detail. Finally, we summarize failed and ongoing clinical trials using targeted therapies in resistant TGCTs, and analyze the potential of new targeted therapies.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

pubmed, article, google, scholar, testicular, cancer, germ, cell, cas, tumors, oncol, central, urol, clin, van, study, patients, tumours, resistance, cisplatin, cells, germcell, res, gillis, biomarkers, clinical, nat, risk, int, carcinoma, honecker, stoop, pathol, ajm, serum, phase, molecular, mechanisms, diagnostic, diagnosis, looijenga, lhj, human, jong, genet, micrornas, refractory, privacy, cookies, content,

Topics {✒️}

testicular germ-cell tumours testicular germ-cell tumors month download article/chapter refractory germ-cell tumors relapsed germ-cell tumors testicular germ-cell cancer germ-cell testicular cancer autologous stem-cell transplant germ cell tumours cell-free circulating dna fetal germ cells germ cell tumors germ-cell tumors genome-wide association study testis-specific rnf4 transcript p53-mediated apoptosis de bekker-grob ew rajpert-de meyts genome-wide association studies routine care-registry data bevacizumab/high-dose chemotherapy large population-based analysis thierry roumeguère declare germ cell neoplasia review article published full article pdf embryonic origin germ cells human testicular cancer kanetsky pa outcomes research project einhorn lh privacy choices/manage cookies microdissected cell populations cell death dis phase ii study testicular cancer survival testicular cancer--experiences support care cancer stem cells cisplatin-based chemotherapy testicular cancer incidence testicular dysgenesis syndrome hampig raphael kourie cell oncol dordr case–control study related subjects cook mb circulating mitochondrial dna de krijger rr

Questions {❓}

Serum levels of microRNAs miR-371-3: a novel class of serum biomarkers for testicular germ cell tumors?
Will Testicular Germ Cell Tumors Remain Untargetable?
Will Testicular Germ Cell Tumors Remain Untargetable?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Will Testicular Germ Cell Tumors Remain Untargetable?
         description:Testicular Germ cell tumors (TGCT) represent the most common solid tumors affecting young men. They constitute a distinct entity because of their embryonic origin and their unique biological behavior. Recently, new preclinical data on genetic and epigenetic susceptibility profiles, biological signaling machinery as well as on molecular patterns of tumors and pathways of pathogenesis helped to elucidate the pathogenesis and the differentiation of TGCTs and to understand the mechanisms behind the development of resistance to treatment. In the present work, we have reviewed new clues to the development, differentiation and progression of TGCTs. We focus on the most important epigenetic and molecular biomarkers, and discussed their diagnostic and prognostic accuracy compared to the currently used biomarkers. The mechanisms underlying the development of resistance to cisplatin and commonly used chemotherapeutic agents are also discussed in detail. Finally, we summarize failed and ongoing clinical trials using targeted therapies in resistant TGCTs, and analyze the potential of new targeted therapies.
         datePublished:2016-05-17T00:00:00Z
         dateModified:2016-05-17T00:00:00Z
         pageStart:711
         pageEnd:721
         sameAs:https://doi.org/10.1007/s11523-016-0439-4
         keywords:
            Germ Cell Tumor
            Testicular Cancer
            Pazopanib
            Seminoma
            Merkel Cell Carcinoma
            Oncology
            Biomedicine
            general
         image:
         isPartOf:
            name:Targeted Oncology
            issn:
               1776-260X
               1776-2596
            volumeNumber:11
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Fouad Aoun
               affiliation:
                     name:Hôtel Dieu de France
                     address:
                        name:Department of Urology, Hôtel Dieu de France, Beyrouth, Lebanon
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Hampig Raphael Kourie
               affiliation:
                     name:Jules Bordet Institute
                     address:
                        name:Department of Oncology, Jules Bordet Institute, Brussels, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Simone Albisinni
               affiliation:
                     name:Erasme Hospital
                     address:
                        name:Department of Urology, Erasme Hospital, Brussels, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thierry Roumeguère
               affiliation:
                     name:Erasme Hospital
                     address:
                        name:Department of Urology, Erasme Hospital, Brussels, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Will Testicular Germ Cell Tumors Remain Untargetable?
      description:Testicular Germ cell tumors (TGCT) represent the most common solid tumors affecting young men. They constitute a distinct entity because of their embryonic origin and their unique biological behavior. Recently, new preclinical data on genetic and epigenetic susceptibility profiles, biological signaling machinery as well as on molecular patterns of tumors and pathways of pathogenesis helped to elucidate the pathogenesis and the differentiation of TGCTs and to understand the mechanisms behind the development of resistance to treatment. In the present work, we have reviewed new clues to the development, differentiation and progression of TGCTs. We focus on the most important epigenetic and molecular biomarkers, and discussed their diagnostic and prognostic accuracy compared to the currently used biomarkers. The mechanisms underlying the development of resistance to cisplatin and commonly used chemotherapeutic agents are also discussed in detail. Finally, we summarize failed and ongoing clinical trials using targeted therapies in resistant TGCTs, and analyze the potential of new targeted therapies.
      datePublished:2016-05-17T00:00:00Z
      dateModified:2016-05-17T00:00:00Z
      pageStart:711
      pageEnd:721
      sameAs:https://doi.org/10.1007/s11523-016-0439-4
      keywords:
         Germ Cell Tumor
         Testicular Cancer
         Pazopanib
         Seminoma
         Merkel Cell Carcinoma
         Oncology
         Biomedicine
         general
      image:
      isPartOf:
         name:Targeted Oncology
         issn:
            1776-260X
            1776-2596
         volumeNumber:11
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Fouad Aoun
            affiliation:
                  name:Hôtel Dieu de France
                  address:
                     name:Department of Urology, Hôtel Dieu de France, Beyrouth, Lebanon
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Hampig Raphael Kourie
            affiliation:
                  name:Jules Bordet Institute
                  address:
                     name:Department of Oncology, Jules Bordet Institute, Brussels, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Simone Albisinni
            affiliation:
                  name:Erasme Hospital
                  address:
                     name:Department of Urology, Erasme Hospital, Brussels, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thierry Roumeguère
            affiliation:
                  name:Erasme Hospital
                  address:
                     name:Department of Urology, Erasme Hospital, Brussels, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Targeted Oncology
      issn:
         1776-260X
         1776-2596
      volumeNumber:11
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hôtel Dieu de France
      address:
         name:Department of Urology, Hôtel Dieu de France, Beyrouth, Lebanon
         type:PostalAddress
      name:Jules Bordet Institute
      address:
         name:Department of Oncology, Jules Bordet Institute, Brussels, Belgium
         type:PostalAddress
      name:Erasme Hospital
      address:
         name:Department of Urology, Erasme Hospital, Brussels, Belgium
         type:PostalAddress
      name:Erasme Hospital
      address:
         name:Department of Urology, Erasme Hospital, Brussels, Belgium
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Fouad Aoun
      affiliation:
            name:Hôtel Dieu de France
            address:
               name:Department of Urology, Hôtel Dieu de France, Beyrouth, Lebanon
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Hampig Raphael Kourie
      affiliation:
            name:Jules Bordet Institute
            address:
               name:Department of Oncology, Jules Bordet Institute, Brussels, Belgium
               type:PostalAddress
            type:Organization
      name:Simone Albisinni
      affiliation:
            name:Erasme Hospital
            address:
               name:Department of Urology, Erasme Hospital, Brussels, Belgium
               type:PostalAddress
            type:Organization
      name:Thierry Roumeguère
      affiliation:
            name:Erasme Hospital
            address:
               name:Department of Urology, Erasme Hospital, Brussels, Belgium
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Urology, Hôtel Dieu de France, Beyrouth, Lebanon
      name:Department of Oncology, Jules Bordet Institute, Brussels, Belgium
      name:Department of Urology, Erasme Hospital, Brussels, Belgium
      name:Department of Urology, Erasme Hospital, Brussels, Belgium
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(268)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js
Raphael

4.2s.

LINK . SPRINGER . COM {}